Weinstein reports 4.01% stake in Precision BioSciences
PRECISION BIOSCIENCES INC (DTIL) received an amended Schedule 13G/A reporting the holdings of Benjamin Weinstein in its common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PRECISION BIOSCIENCES INC (DTIL) received an amended Schedule 13G/A reporting the holdings of Benjamin Weinstein in its common stock.
Weinstein reports 1,105,720 shares beneficially owned, including 203,500 shares issuable upon exercise of warrants, representing 4.01% of the common stock. The percentage is based on 27,601,554 shares outstanding as of August 3, 2026. He reports sole and shared voting and dispositive power over the same 1,105,720 shares and confirms ownership of 5% or less of the class.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
dispositive power financial
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of PRECISION BIOSCIENCES INC (DTIL) does Benjamin Weinstein report owning in this Schedule 13G/A?
What portion of Benjamin Weinstein’s DTIL position comes from warrants?
Does this Schedule 13G/A indicate that Benjamin Weinstein owns 5% or more of DTIL?
AI-generated analysis. How Rhea-AI works. Not financial advice.